RecruitingNCT07527143
Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer
Sponsor
Mayo Clinic
Enrollment
25 participants
Start Date
Jun 10, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.
Eligibility
Sex: FEMALEMin Age: 45 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying Non-Interventional Study for people with endometrial carcinoma. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 45 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07527143
Related Trials
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225409 locations
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT0591926433 locations
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT056910107 locations
GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education
NCT072795712 locations
Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding
NCT063659053 locations